The correlation of XXXX serum levels with the presence of @entity253 .

@entity1 @entity10921 @entity788 @entity656 @entity1904 @entity1448 @entity253
INTRODUCTION: There is still no general agreement as to which @entity1 suffering from attacks of @entity656 should undergo emergent endoscopic retrograde cholangiopancreatography (ERCP) with subsequent endoscopic intervention (endoscopic papilotomy, stent placement etc.). Many authors have described large differences in @entity1904 (PTC) serum levels in @entity1 suffering from @entity788 as opposed to @entity1 whose acute @entity788 is based on toxic etiology. Therefore, we have investigated the correlation of @entity1904 serum levels with the presence of @entity253 in @entity1 undergoing ERCP examination. MATERIAL AND METHODS: From 1.8.2004 to 31.3.2005, 97 @entity1 undergoing ERCP were enrolled into the study. Blood samples were taken from each @entity1 just before their ERCP examinations, and @entity10921 serum levels were subsequently correlated to ERCP findings. RESULTS: ERCP examinations were completed in 90 out of 97 @entity1 . @entity1448 were confirmed in 61 out of 90 @entity1 and the mean serum level of PTC was 0.078 ng/ml. In the remaining 29 @entity1 ERCP revealed normal findings and the mean @entity10921 value was 0.069 ng/ml. There was no statistical correlation between @entity10921 serum levels and the presence of @entity253 on ERCP findings. CONCLUSION: The measurement of @entity10921 serum levels is of no help in the identification of @entity1 , who should undergo emergent ERCP due to @entity656 (Tab. 1, Fig. 1, Ref. 6).
